The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically ...

The EMA's CHMP has recommended approval of a combination therapy of BMS's Opdivo and Yervoy for the treatment of colorectal ...

At AHA 2024, clinical trial results were presented from the ongoing open-label extension trial, LIBERATE-OLE, involving ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

The US Food and Drug Administration (FDA) has approved Azurity Pharmaceuticals’ Danziten (nilotinib), the first and only ...

The Danish infectious disease specialist has $340m (DKK 2.4m) lined up through orders for its MVA-BN vaccine known under the ...

Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...